703-433-2362

ю. 1

RECEIVED
CENTRAL FAX CENTER

JUL 0 9 2007

251 North Avenue West, 2nd Floor Westfield, NJ 07090

Mayer & Williams, PC Attorneys At Law



To:	Com	nmissioner for Paten	ts	From:		vid Bonham 3) 433-0510
Fax:	571-273-8300		Total pages: 3			
Phone	:			Date:	7/9/	2007
Re:	In connection with Serial No. 10/748,117, please find enclosed a response to the Office communication dated June 11, 2007. Sincerely.					
	David Bonham					
□ Urg	ent	☐ For Review	☐ Please Comment	☐ Please Re	eply	☐ Piease Recycle
		PRIVACY A	ND CONFIDENTIA	LITY NO	TICE	
for the intende	use of d recip	the individual or entity pient, you are hereby	mmunication is confidential a to whom it is addressed and notified that any disclosure nation is strictly prohibited.	others authorize	ed to rec	elve it. If you are not the
			n eπor, please immediately n uments to us at the above ad			

p.2

CENTRAL FAX CENTER

JUL 0 9 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Derek O'Hagan et al.

Serial No.:

10/748,117

Filed:

12/29/2003

Title:

IMMUNOGENIC COMPOSITIONS CONTAINING PHOSPHOLIPIDS

Art Unit:

1645

Examiner:

Nita M. Minnifield

Confirm. No.: 1746

Docket No.: PP020038.003

Via Facsimile: 571-273-8300 Mail Stop Amendment

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO OFFICE COMMUNICATION ALLEGING THAT REPLY FILED 4/16/07 WAS NOT FULLY RESPONSIVE TO PRIOR OFFICE ACTION

Sir:

This is responsive to the Office communication dated June 11, 2007, in which it was alleged that the reply filed April 16, 2007 is not fully responsive to the prior Office Action, because: "Applicants did not respond to the species election in the Restriction Requirement (see page 5) mailed January 16, 2007."

A review of page 5 of the Restriction Requirement mailed January 16, 2007, indicates that two species elections were required: an antigen and a phospholipid. It is believed that these species elections were properly made in applicants reply to that Restriction Requirement, which was filed April 16, 2007.

In particular, at the bottom of page 18 of Applicant's prior reply (available on PAIR), Applicant elected meningitis B as the antigen. Applicant further elected the phospholipid of claim 9 as the phospholipid compound. All parameters (e.g., R¹, a, b, d, d', e, e', d", e", X¹, X², Serial No.: 10/748,117

Y¹, Y², W¹, W², R², R⁵, R³, R⁶, R⁴, R⁷, G¹, G², G³, G⁴) are believed to be defined in claim 9. (These parameters define a compound like that found in paragraph [0079] of the specification.)

To the extent that the Examiner wishes to maintain this rejection, further clarification is requested. It is believed that any further issues in this species election could be readily resolved by a telephone call to the undersigned, and such a call would be welcomed.

Attorney for Applicant Mayer & Williams, PC 251 North Avenue West, 2nd Floor Westfield, NJ 07090

Tel.: 703-433-0510 Fax: 703-433-2362

Please continue to direct all correspondence to:
Novartis Vaccines and Diagnostics Inc.
Corporate Intellectual Property R338
P.O. Box 8097
Emeryville, CA 94662-8097

Respectfully submitted,

David B. Bonham Registration No. 34,297

I hereby certify that this correspondence is being deposited with the United States Patent and Trademark Office on Quy 7,207 via facsimile to: 571-273-8300.

David B. Bonham

(Printed Name of Person Mailing Correspondence)

(Signature)